Medical Cannabis for PTSD UK — What the Research Says

Post-traumatic stress disorder (PTSD) affects an estimated 4% of UK adults at any time. Medical cannabis has emerged as a promising treatment option for PTSD, particularly for patients who have not responded to conventional therapies such as SSRIs and CBT. The endocannabinoid system plays a key role in fear memory consolidation and extinction — the processes disrupted in PTSD. Cannabis compounds, particularly CBD and THC, interact with this system to potentially reduce hyperarousal, improve sleep quality and diminish the intensity of traumatic memories. UK specialists treating PTSD typically prescribe CBD-dominant or balanced products initially, progressing to THC-containing products where needed. Indica and hybrid strains are preferred over sativas, which can sometimes increase anxiety. Mamedica, Lyphe and Sapphire Medical Foundations all have experience treating PTSD with medical cannabis. Patients should expect to try several products before finding the optimal formulation. Use LeafMe to compare PTSD clinic options.